Overcome Analytical Method Validation. Top Challenges!
|
|
- Judith McKenzie
- 6 years ago
- Views:
Transcription
1 Overcome Analytical Method Validation Top Challenges! December 8, 2015 Lina Patel, Ph.D. Director, Quality Operations Laboratories IVT s Lab Week Series Analytical Procedures and Methods Validation December 8-10, 2015 Philadelphia, PA 1
2 Overview Strategies for moving existing analytical test methods to newer technologies within site, site to site Challenges during technology transfer of validated test methods site to site How to avoid some common pitfalls? 2
3 Existing Test Methods to New Technologies For Biological assays Steps within the assay process not necessarily replacing the assay Manual operation to automation such as: plaque counting sample diluting pipetting labeling For Microbiology assays Sterility direct to rapid 3
4 Existing Test Methods to New Technologies New Challenges Developing technology support Equipment, Automation Building expertise and skill Finding unexpected problems Developing implementation strategy regulatory approvals and product release Meeting expectations! is release time faster? Risks and Impact to change in the current laboratory environment Resource constraints training & testing Potential delay in product release 4
5 Technology Transfer of Validated Methods Top challenges Method developed and validated on equipment model not current new model, different factory settings Method not optimized since first developed High variability Assay acceptance criteria based on limited data Standard Operating Procedures not clear Assay process not lean 5
6 How to avoid some common pitfalls? Good Scientific Practice Team Agreement who is the team? Review Method Validation Process Assay Development Analytical Procedures Pre-validation, Optimization, Qualification Determine sources of variability Understand method Parameters Characterization studies Good Documentation Practices 6
7 Good Scientific Practices Assay Development Scientifically sound and appropriate Repeatable Robust Good Documentation Practice Real time documentation Clear to follow methods Training Data Verified/Reviewed Calculations transparent Reproducible 7
8 Team all the right people? Groups Analytical Development Quality Laboratories Technical Experts Statisticians Marketing? Regulatory! Site to Site (Team agreement critical otherwise project can get derailed) 8
9 Team Agreement Quality Stakeholders Scientists AD /QC/SME/ Statisticians 9
10 Review of Method Validation Process Assay Development Analytical Procedure Prevalidation/ Optimization Qualification/ Method Validation Revalidation Check the necessary conditions for Methods, Material Standards, Controls, Reagents Equipment, Instrumentation 10
11 Assay Development Subject Matter Experts /Cross functional team Analytical Development QC Laboratory Technology Manufacturing Engineering Automation/IT QA Method & Materials Multivariate experiments Assay Development Standards, Controls & Reagents Equipment & Instrumentation Project Plan - monitor progress Organize documents 11
12 Analytical Procedure Stepwise instructions Clear process flow Equipment set up, operating parameters Reagents, Reference/Standard preparation, special handling, expiry date Sample preparation critical aspects? System Suitability criteria Assay acceptance criteria Calculations Data Reporting data forms, self directed, prompts 12
13 Pre-validation, Optimization, Qualification Equipment/ Instrument Laboratory environment (temp, humidity) Handling of Sample, Reference & Reagent Training Determine Sources of Method Variation Understand Method Parameters System suitability Assay acceptance Reference & reagent qualifications Assay critical parameters Automation Accelerated/Stability Studies Degradation studies Identity, Purity, etc. Characterization Studies & Analyses Good Documentation Practices Organization of raw data, notebooks, etc. Data verification Test method Roadmap Procedure visual guidance Data documentation sheets/forms 13
14 Determine Sources of Variation Sample Source of material Research material, clinical material, process validation, Handling conditions Storage, bench top handling, thawing process, equilibrating process Preparation Dilution automated pipetting? liquid handling system? Mixing 14
15 Determine Sources of Variation Standards, Controls, Reagents General handling Storage conditions, e.g. light sensitive? thawing process, equilibrating process, e.g. room temperature, water bath/incubator Vendor changes Grade changes Preparation Mixing Expiry date (freshly prepared?) 15
16 Determine Sources of Variation 16 Equipment, Instrumentation Qualified, calibrated Model changes/upgrades? Example: Automated pipetting, Moisture analysis Vendor changes Example: Chromatography columns, capillaries Technical differences? Example: Spectrophotometer dual beam, single beam, diode array Laboratory Environment Humidity control, Temperature control
17 Determine Sources of Variation Training Resources - Trainers Subject Matter Experts maybe located off-site Turnover laboratory personnel and contractors Challenges to sustain cohesive training plan after implementation 17
18 Understand Method Parameters System Suitability Criteria System Suitability Standard Define optimal settings e.g. Chromatography assays flow rate, column temperature, run time, detector settings Generally based on small data set Assay Acceptance Criteria Reference Standard/Material Qualification Periodic/real time control charts, monitor drift 18
19 Understand Method Parameters Automation check Parameters set upon qualification Monitor system breakdown Monitor system upgrades Raw Data Server LIMS LIMS Link 19
20 Good Documentation Practices Test method Provides roadmap Controls changes Provides visual guidance, where necessary Data documentation forms/sheets Clear, self directed Raw data and notebooks Data verification 20
21 in a nutshell Ensure Good Scientific Practices Team Agreement, engagement and support from project planning, knowledge transfer, troubleshooting to reagent supply, equipment operation/maintenance, automation Review Method Validation Process Assay Development new or process improvement Analytical Procedures key to consistent execution Pre-validation, Optimization, Qualification Determine sources of variability monitor, review Understand Method Parameters monitor, review Characterization studies help in troubleshooting Good Documentation Practices ALWAYS! 21
22 Regulatory Guidance Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics (Feb 2014) Guidance for Industry: Analytical Procedures and Methods Validation (Aug 2000) Guidance for Industry: Submitting Samples and Analytical Data for Methods Validation (Feb 1997) Content and Format of Investigation New Drug Applications (INDs) for Phase I Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. IND Meetings for Human Drugs and Biologics, Chemistry, Manufacturing, and Controls Information. Q2A: Text on Validation of Analytical Procedures (Mar 1995) Q2B: Validation of Analytical Procedures: Methodology (Nov 1996) Q6A, Q6B: Specifications (Dec 2000, Aug 1999) Q8 (R2): Pharmaceutical Development (Nov 2009) Q9: Quality Risk Management (Jun 2006) Q10: Pharmaceutical Quality System (Apr 2009) EMEA Guidance on Validation of Analytical Procedures: Text and Methodology 22
23 Expectation It is the responsibility of the applicant to choose the validation procedure and protocol most suitable of their product. The main objective of validation of an analytical procedure is to demonstrate that the procedure is suitable for its intended purpose. Well characterized reference materials, with documented purity should be used throughout the validation study. The degree of purity necessary depends on the intended use. All relevant data collected during validation and formulae used for calculating validation characteristics should be submitted and discussed as appropriate 23
24 Note New Analytical & Method Validation Guidance explicit on: Lines , If an analytical procedure can only meet the established system suitability requirements with repeated adjustments to the operating conditions stated in the analytical procedure, the analytical procedure should be reevaluated, revalidated, or amended, as appropriate. EMEA Guidance: Section 6.4: Quality Control personnel should have access to production areas for sampling and investigation as appropriate. 24
25 25 THANK YOU!
Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP
Analytical Method Transfer Program Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP Outline Requirements for an AMT Program Develop Your AMT Program Qualify Your AMT Program On-going
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Analytical Procedures and Methods Validation for Drugs and Biologics Lucinda (Cindy) Buhse, Ph. D. Acting Director, Office of Testing and Research Office of Pharmaceutical Science CDER, FDA CHPA Quality
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationReplacing Analytical Methods for Release and Stability Testing A Regulatory Perspective
Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh
More information5 KEY STEPS TO A SUCCESSFUL LABORATORY RELOCATION
5 KEY STEPS TO A SUCCESSFUL LABORATORY RELOCATION Author: John Best Global Relocation Services Leader PerkinElmer, Inc. GET STARTED Relocating a laboratory, whether down the hall or to another continent,
More informationOverview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationBasic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D
Basic Good Laboratory Practice Christopher Jerome, B.Vet.Med., Ph.D Goals Outline the concept of Good Laboratory Practice (GLP) Provide some specific guidelines applicable to day to day work in the laboratory
More informationICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP
USP ICH Q2(R1) A Primer GxP cgmp PIC/S SOP ISO 17025 QA/QC LOD/LOQ API EP Validation of Analytical Methods FDA OECD GCP Validation of Analytical Methods Ludwig Huber Contents Preface...............................................
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationLaboratory Reagents. for life science research.
Laboratory Reagents Research, quality control, or routine analysis whatever the field of activity, where there is a need for laboratory reagents, Thermo Fisher Scientific has a suitable product. We offer
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationBreaking the Silo Mentality Working With Opinion Leaders
CBI s 2 nd Annual KOL Conference Breaking the Silo Mentality Working With Opinion Leaders Kashif Chaudhry Objectives Share a view on the changing environment impacting the pharmaceutical industry and KOL
More informationAgilent solutions for contract research and manufacturing organizations
Agilent solutions for contract research and manufacturing organizations Cooperation between pharmaceutical companies and contract research organizations A successful approach to increasing efficiency along
More informationCDASH Clinical Data Acquisition Standards Harmonization
CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationGDRP Guideline. Reliable Results for Density and Refractive Index
GDRP Guideline GDRP TM Limit risks Minimize errors Improve quality Reduce costs Protect your investment Reliable Results for Density and Refractive Index Improve Lab Processes GDRP What is it Exactly?
More informationSymphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results
Symphony Genomics Workflow Management System Managing, Integrating, and Delivering Your NGS Data and Results Precision Genomics for Immuno-Oncology www.personalis.com info@personalis.com 1 855-GENOME4
More informationAt Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance
More informationOutsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing
Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationReducing Risk and Costs in the Global Supply Chain
Reducing Risk and Costs in the Global Supply Chain Global Quality & Compliance Services for the Life Sciences Industry sensitech.com @sensitech Protecting the Life Sciences Supply Chain Can Be Costly Maintaining
More informationQualification of High-Performance Liquid Chromatography Systems
Qualification of High-Performance Liquid Chromatography Systems L. Huber Hewlett- Packard GmbH, Waldbronn December 1998 Manuscript of an article published in BioPharm, Vol 11 Number 11, November 1998,
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances
More informationQualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014
Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014 Introduction EU Clinical Trials Directive 2001 came into existence in the UK in May 2004 (Part 6 Manufacture of Investigational
More informationSESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt
Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationPMDA Perspective: Regulatory Updates on Process Validation Standard
CMC Strategy Forum Japan 2014 Tokyo, Japan, December 8-9, 2014 PMDA Perspective: Regulatory Updates on Validation Standard Kazunobu Oyama, PhD Office of Cellular and Tissue-based Products PMDA, Japan Disclaimer:
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental
More informationRecent FDA Inspection Findings and Trends
Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11
More informationIntroduction to 21 CFR 11 - Good Electronic Records Management
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article Introduction to 21 CFR 11 - Good Electronic Records Management Pal Tapas Kumar* and Maity Subhasis NSHM Knowledge Campus,
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationA24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018
A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 Laboratory Name: Appendix Name: Appendix Number: Assessor: Date: Rev. 4.1 CALA CHECKLIST FOR MICROBIOLOGY Item 01 SAMPLING AND SAMPLE
More informationStrategies for Risk Based Validation of Laboratory Systems
Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,
More informationQUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY
QUALITY CONTROL/QUALITY ASSURANCE IN THE MOLECULAR MICROBIOLOGY LABORATORY Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationPhysicists Quality Control for MR Equipment
Physicists Quality Control for MR Equipment Geoffrey D. Clarke, Ph.D. University of Texas Health Science Center at San Antonio 1 Overview ABR and the role of the Qualified Medical Physicist/ MR Scientist
More informationSupplies and Reagents
Supplies and Reagents PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 NHLBI-sponsored PACT Group Guidance for Industry INDs Approaches to Complying with CGMP During
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationFacility and Equipment Maintenance
Facility and Equipment Maintenance Deborah L. Griffin Manager, Quality Assurance for Cellular Therapies Hillman Cancer Center University of Pittsburgh Cancer Institute University of Pittsburgh Medical
More informationUSP <1116> and Contamination
USP and Contamination Recovery Rates Scott Sutton ABSTRACT United States Pharmacopeia (USP) "Microbiological Control and Monitoring of Aseptic Processing Environments" approaches analysis
More informationJob Title: Cell Culture Technician (open June 1 through Oct 31, 2016)
Rockland Immunochemicals Inc. is recognized as one of the world's leading manufacturers and suppliers of immunochemical reagents for basic research and discovery. Rockland Immunochemicals provides reagents
More informationBEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development
- ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,
More informationAnalytical and formulation attributes
Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding
More informationPhase Appropriate Method Validation
Phase Appropriate Method Validation Aryo Nikopour Irvine, California January 12, 2017 The Southern California Pharmaceutical Discussion Group (SCPDG) of AAPS OUTLINE What is Validation Guidelines Method
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationOMPQ Update: Quality Systems and Drug Lifecycle Risk Management
OMPQ Update: Quality Systems and Drug Lifecycle Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing & Product Quality FDA/CDER/OC FDA Inspections Summit October 22, 2014
More informationValidation Strategies for Equipment from Multiple Vendors
Welcome to our E-Seminar: Validation Strategies for Equipment from Multiple Vendors Page 1 Content FDA guidelines and inspectional observations Validation & Qualification Approaches Instrument Qualification
More informationRADON MEASUREMENT OA - PRACTICE vs PROTOCOLS
RADON MEASUREMENT OA - PRACTICE vs PROTOCOLS Raymond Johnson, Sandy Colon, and Douglas Heim, Key Technology, Inc. Jonestown, PA ABSTRACT The EPA radon measurement device protocols of July 1992 specify
More informationLaboratory Data Collection, Analysis, Interpretation and Management
Laboratory Data Collection, Analysis, Interpretation and Management Agenda Overview of OpenLAB (CDS, ELN, ECM) OpenLAB CDS Remote Control (AIC) OpenLAB Collaboration (remote access) OpenLAB Demo Wrap up
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationRisk-based Approach to Part 11 and GxP Compliance
Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!
More informationThe validation of biological Active Pharmaceutical
This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements
More informationCOURSE LISTING. Courses Listed. with Business Intelligence (BI) Crystal Reports. 26 December 2017 (18:02 GMT)
with Business Intelligence (BI) Crystal Reports Courses Listed BOC345 - SAP Crystal Reports 2011: Optimizing Report Data Processing BOC320 - SAP Crystal Reports: - BOCE10 - SAP Crystal Reports for Enterprise:
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More informationZydus Hospira Oncology Pvt. Ltd.
Company, Position & Person Profile Zydus Hospira Oncology Pvt. Ltd. 6/7/15 About Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Private Limited (ZHOPL) is a joint venture company in Ahmedabad,
More informationFlorida Department of TRANSPORTATION Materials Acceptance and Certification (MAC) System
Materials Acceptance and Certification (MAC) System FTBA 2/11/2014 Presented By David Davis, Susan Blazo 1 The 5 W s Business Perspective Who will be affected by MAC Asphalt Production Facility QC Managers
More informationEnhancement will increase speed and accuracy of data collection during sample preparation. Additional space is needed for HCR scope testing
NUMBER CC01398 2016 CHANGE CATEGORY Major Software REQUESTED CHANGE REASON FOR CHANGE IMPACT APPROXIMATE DATE IMPLEMENTED BET Uniflow system enhancement to allow batch data collection for Prep device,
More informationMost products in discovery
FOCUS ON... OUTSOURCING Accelerating Bioassay Transfer in a GMP Environment by Ana T. Menendez Most products in discovery by pharmaceutical companies today are biopharmaceuticals. Made by living organisms,
More informationZydus Hospira Oncology Pvt. Ltd.
Company, Position & Person Profile Zydus Hospira Oncology Pvt. Ltd. 6/7/15 About Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Private Limited (ZHOPL) is a joint venture company in Ahmedabad,
More informationInvisible Ink in GLP and GCP Research
http://www.colginconsulting.com/invisible-ink-in-glp-and-gcp-research/ Invisible Ink in GLP and GCP Research What follows is more or less a transcript of my presentation at the annual meeting of the Pacific
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationDeveloping a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods
Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility,
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationModeling Your Water Balance
Modeling Your Water Balance Purpose To model a soil s water storage over a year Overview Students create a physical model illustrating the soil water balance using glasses to represent the soil column.
More informationValidation of Impurity Methods, Part I
626 LCGC NORTH AMERICA VOLUME 21 NUMBER 7 JULY 2003 www.chromatographyonline.com Validation Viewpoint John D. Orr, Ira S. Krull, and Michael E. Swartz This column is the first installment in a two-part
More informationContinuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation
Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation Christina Capacci-Daniel, Ph.D. Consumer Safety Officer / Acting Quality Assessment
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationLatest USP Initiatives: Monographs, General Chapters, and Compounding
Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationNADERI ENGINEERING, INC.
BIO-PHARMACEUTICAL ENGINEERING & VALIDATION CAPABILITIES "Cost Effective Solutions Through Innovation" 1240 Powell Street, Suite 2-B Emeryville, CA 94608 Tel: (510) 547-4040 Fax: (510) 547-4141 Website:
More informationCalibration in the Laboratory
IVT Validation Week 2015 Calibration in the Laboratory 2015 The Lanese Group, Inc. Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Outline Overview of laboratory data integrity Elements of the Laboratory Instrument
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationProposed New USP General Chapter: The Analytical Procedure Lifecycle 1220
Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure
More informationTerms of Reference Governance Committee
1. Purpose Terms of Reference Governance Committee The Governance Committee is responsible for ensuring that BC Assessment and its Board develop and implement an effective approach to corporate governance.
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
More informationINDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW
International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute
More informationSynthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013
Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs
More information